<?xml version="1.0" encoding="UTF-8"?>
<p>Data obtained from the US reported an apparent lack of LAIV effectiveness in the 2015/2016 influenza season, especially toward A/H1N1 vaccine component. Such results have led the Advisory Committee on Immunization Practices (ACIP) not to use the LAIV in the US during the 2016/2017 seasons.
 <xref rid="irv12664-bib-0056" ref-type="ref">56</xref> Conversely from the observations reported in the US, a higher overall protection of the LAIV against laboratory‚Äêconfirmed infection with the A/H1N1 strain in comparison with IIV has been reported by the UK
 <xref rid="irv12664-bib-0057" ref-type="ref">57</xref> and Finland in the 2015/2016 season.
 <xref rid="irv12664-bib-0058" ref-type="ref">58</xref> For these reasons, LAIV use is closely monitored, but it is still recommended in these countries as well as in Norway, although the motives underlying this difference have not been elucidated yet.
</p>
